Mahmood Shakir Khudhair

Mahmood Shakir Khudhair

Auto-generated profile, based on publicly available information

Mahmood Shakir Khudhair

Scientific Committee for the Study of Diabetes and Endocrinology at the Iraqi Board of Medical Specialties, Baghdad, Iraq

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in Journal of Associated Medical Sciences
Verified
Journal Article
Open access
SASajjad Ashour
Sajjad Ashour
MHMohammed Hamzah
Mohammed Hamzah
MKMahmood Shakir Khudhair
Mahmood Shakir Khudhair
Background: Meteorin-like protein (Metrnl) is an adipokine mostly produced and secreted by adipose tissue. Metrnl is an adipokine that enhances insulin sensitivity, promotes the browning of adipose tissue, and increases energy expenditure. Objectives: This study aimed to investigate alterations in serum Metrnl levels in patients with Graves’ disease (GD) and subclinical hyperthyroidism (SCH), with the objective of assessing its potential as a diagnostic biomarker. Materials and methods: This case-control study was matched for age, sex, and BMI and included 40 patients with GD, 40 with SCH, and 80 controls. The average ages of the participants ranged from 22 to 59 years. Samples were obtained from July 2025 to January 2026. Metrnl levels were measured using a sandwich enzyme-linked immunosorbent assay. T4 and TSH levels were evaluated using the VIDAS system (bioMérieux), whereas thyroid-stimulating hormone receptor antibodies (TRAb) were detected using the Roche Cobas e411 Analyzer. The Roche Cobas c111 Analyzer was employed to evaluate lipid profiles. Results: The mean serum Metrnl levels in the control group were 11.7±1.9 ng/mL. In contrast, patients with GD had a significantly elevated mean Metrnl level of 22.1±2.3 ng/mL (p<0.001). The SCH group had a markedly elevated mean concentration of 22.4±2.8 ng/mL (p<0.001) compared to the control group. Serum concentrations of TSH, total cholesterol, triglycerides, LDL, and VLDL were markedly reduced in both GD and SCH relative to controls (p<0.001). T4 and TRAb levels were significantly elevated in GD and SCH compared with controls (p<0.001). Conclusion: Elevated levels of Metrnl in Graves’ disease suggest its potential as a new biomarker for diagnosis and evaluation of metabolic risks, alongside conventional thyroid function tests.

15 April 2026 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
CSCharles Saab
Charles Saab
AMAbbas Ali Mansour
Abbas Ali Mansour
ARAbbas Mahdi Rahmah
Abbas Mahdi Rahmah
DADelman Raoof Al-Attar
Delman Raoof Al-Attar
HAHaidar Fadhil Al-Rubay’E
Haidar Fadhil Al-Rubay’E
TMTaha Othman Mahwi
Taha Othman Mahwi
Introduction Type 2 diabetes mellitus (T2DM) prevalence in Iraq is projected to rise significantly by 2045, creating urgent need for optimized use of latest insulin therapies. An expert panel of eleven diabetes specialists convened to assess the evolving landscape of insulin therapies and explore how each option fits into current strategies to optimize T2DM management in Iraq. Methods The panel reviewed international guidelines and local practice patterns through pre-meeting surveys. Discussions focused on initiation and intensification of insulin-based treatment in Iraq's context, considering accessibility challenges and patient characteristics. Results When hemoglobin A1c (HbA1c) is < 2% above target, basal insulin (BI) is recommended for patients with body mass index (BMI) ≤ 30. For BMI > 30, either GLP-1 receptor agonist (GLP-1 RA) monotherapy or a fixed ratio combination (FRC) of GLP-1 RA and BI is preferred. When HbA1c is ≥ 2% above target, initiation with BI and GLP-1 RA is advised across BMI groups. If glycemic targets are not achieved despite reaching 0.5 U/kg of BI, prandial insulin may be added via premixed regimen or basal–bolus regimens based on individual factors. Premix insulin remains an alternative when other options are unavailable. Key barriers in Iraq include high cost and limited availability of GLP-1 RAs, therapeutic inertia, and gaps in healthcare infrastructure. Final treatment decisions should consider disease severity, cardiovascular and renal comorbidities, and weight goals. Conclusion The panel curated clinical practical recommendations about injectable insulin therapies and proposed a structured treatment algorithm tailored to Iraq’s healthcare setting, prioritizing simplicity, efficacy, tolerability and accessibility. The panel emphasized the critical role of second-generation BIs and FRCs of BI and GLP-1 RA in Iraq’s T2DM treatment algorithm, providing clear guidance on their optimal use and place in therapy, overcoming barriers, alongside enhanced education for healthcare providers and patients.